LEVELS OF BCL2 EXPRESSION AT POST-INDUCTION AND AT COMPLETE REMISSION IMPACT THE OUTCOME IN AML AND MAY IDENTIFY THOSE PATIENTS THAT WOULD BENEFIT OF BCL2 INHIBITORS: PB1689